Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of BR1400 in Healthy Volunteers
NCT06889064Phase 1Completed
- Sponsor
- Boryung
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BR1400-1 in essential hypertension (3 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve from time 0 to time t and Maximum Plasma Concentration. Started Sep 2024; status: completed.
02
Drugs
BR1400-1
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06889064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889064.